




Treatment-experienced HIV-1 infected patients under salvage regimen with dolutegravir and boosted darunavir: a real-life scenario

Luís Manuel Moura¹; Clara Batista¹; Frederico Duarte¹; Joana Laranjinha¹; Ricardo Correia de Abreu¹; Isabel Neves¹

¹ Infectious Diseases Department - Unidade Local de Saúde de Matosinhos - Hospital Pedro Hispano

Dual therapy with **dolutegravir (DTG)** plus **boosted darunavir with ritonavir or cobicistat (DRV/rc)** is a drug combination with a **robust genetic barrier** and **simple dosing regimen** used in HIV-infected patients, suitable as **salvage therapy** in multi-experienced patients or in cases with documented resistance mutations to multiple classes of antiretrovirals.

Retrospective analysis of the effectiveness of the combined use of DTG and DRV/rc in HIV-1 treatment-experienced patients followed in a district hospital.



Conclusion

Despite the progress in HIV treatment options, multi-experienced patients are still a **challenge**. This study gives an insight into **real-world data** from our clinical experience with the **combination of DTG and boosted DRV**, a valuable option when treating this population.